reverse-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-10. Numbers and descriptions here follow the published literature rather than marketing material.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized cake or fluffy solid |
| Water solubility | High | Dissolves in water and neutral buffers |
| Dry storage | -20 °C or below | Dry, dark, desiccated |
| Reconstituted storage | Frozen, single thaw | Repeated freeze-thaw promotes loss |
| Purity method | Reverse-phase HPLC | Peak area read at 214 or 220 nm |
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Ebselen (also called PZ 51, DR3305, and SPI-1005), is a synthetic organoselenium molecule under preliminary investigation as a drug candidate. It belongs to the class of compounds related to benzene and its derivatives. It is being developed by the Seattle biotechnology company, Sound Pharmaceuticals, Inc. It has also been reported to target tubulin, blocking its polymerization. Ebselen has been entered into clinical trials as a lead compound intended for the potential treatment of various diseases. Its most advanced clinical trial is a Phase III study in people with Meniere's disease, completed in July 2024. In vitro, ebselen is a mimic of glutathione peroxidase and reacts with peroxynitrite. It is purported to have antioxidant and anti-inflammatory properties.
==== Anabolic ==== Bone marrow stimulation: For decades, AAS were the mainstay of therapy for hypoplastic anemias due to leukemia, kidney failure or aplastic anemia. Growth stimulation: AAS can be used by pediatric endocrinologists to treat children with growth failure. However, the availability of recombinant growth hormone, which has fewer side effects, makes this a secondary treatment. Stimulation of appetite and preservation and increase of muscle mass: AAS have been given to people with chronic wasting conditions such as cancer and AIDS. Stimulation of lean body mass and prevention of bone loss in elderly men, as some studies indicate. However, a 2006 placebo-controlled trial of low-dose testosterone supplementation in elderly men with low levels of testosterone found no benefit on body composition, physical performance, insulin sensitivity, or quality of life. Prevention or treatment of osteoporosis in postmenopausal women. Nandrolone decanoate is approved for this use. Although they have been indicated for this treatment, AAS saw little use for this purpose due to their virilizing side effects. Aiding weight gain following surgery or physical trauma, during chronic infection, or in the context of unexplained weight loss. Counteracting the catabolic effect of long-term corticosteroid therapy. Oxandrolone improves both short-term and long-term outcomes in people recovering from severe burns, and is well-established as a safe treatment for this indication. Treatment of idiopathic short stature, hereditary angioedema, alcoholic hepatitis, and hypogonadism.
SIRIUS is a Java-based open-source software for the identification of small molecules from fragmentation mass spectrometry data without the use of spectral libraries. It combines the analysis of isotope patterns in MS1 spectra with the analysis of fragmentation patterns in MS2 spectra. SIRIUS is the umbrella application comprising CSI:FingerID, CANOPUS, COSMIC and ZODIAC. SIRIUS, including its web services for structural elucidation, is freely available to use for academic research. Bright Giant GmbH offers subscription-based access to the SIRIUS web services for commercial users. SIRIUS is not suitable for analyzing proteomics MS data.
Sources: en.wikipedia.org
On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622). In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA. In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business. Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications. In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments). In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments. In January 2017, the company acquired ForSight VISION4. In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price. In November Roche acquired Viewics, Inc. In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business. In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion. In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).
where Ep is potential energy, q is the charge of the particle, and U is the electric potential difference (also known as voltage). When the charged particle is accelerated into time-of-flight tube (TOF tube or flight tube) by the voltage U, its potential energy is converted to kinetic energy. The kinetic energy of any mass is:
== History == In September 2005, Pfizer received a non-approvable letter from the U.S. Food and Drug Administration regarding lasofoxifene (trade name Oporia), a selective estrogen receptor modulator for the prevention of osteoporosis. In January 2008, Ligand Pharmaceuticals, through its marketing partner, Pfizer, submitted a New Drug Application for lasofoxifene, which is expected to be marketed under the tradename Fablyn. Lasofoxifene was approved in the EU under the brand name Fablyn by the EMEA in March 2009.
Sources: en.wikipedia.org
=== Other reactions of biochemical significance === Homocysteine can cyclize to give homocysteine thiolactone, a five-membered heterocycle. Because of this "self-looping" reaction, homocysteine-containing peptides tend to cleave themselves by reactions generating oxidative stress. Homocysteine also acts as an allosteric antagonist at Dopamine D2 receptors. It has been proposed that both homocysteine and its thiolactone may have played a significant role in the appearance of life on the early Earth.
== Structure == ABCC1 is a 190 kDa protein that contains two membrane-spanning domains of hydrophobic nature and two nucleotide binding domains. Each membrane-spanning domain is made up of six α-helices. In addition, the protein also contains a third membrane-spanning domain that sets it apart from other transporters within the ATP-binding cassette family of transporters. The two nucleotide binding domains have a functional asymmetry that plays a significant role in the ability of ATP to power the transporter. The first nucleotide binding domain, which is delegated NBD1, is responsible for the strong attraction of ATP to the transporter. The second nucleotide binding domain, NBD2, is the domain responsible for the hydrolysis of ATP. This asymmetry is specific to the C subfamily of ABC transporters and is generally not found in other transporters. ABCC1 is a highly conserved gene with polymorphisms occurring at very low frequencies of less than five percent. Polymorphisms in this gene are generally found in the form of a single-nucleotide polymorphism (SNP). The greatest ethnic differences in polymorphisms within the ABCC1 are found between Caucasian and Asian populations. There are multiple examples of single nucleotide polymorphisms that are shared among Asian populations but not found in Caucasian populations and vice versa.
The total weight of the breast tissues removed was 44.8 kilograms (99 lb). Another extreme case was observed in 2008 in Maria Vittoria Hospital in Turin, Italy, where the amount removed from both breasts was 17.2 kg (38 lb). The growth occurred during puberty making it a case of juvenile gigantomastia, but the patient did not seek treatment until the age of 29. Another extreme case was observed on August 28, 2003, when a 24-year-old woman was admitted to the Clinical Center Skopje in North Macedonia with gigantomastia of pregnancy and the amount later removed from both breasts was 15 kg (33 lb) in total. A second case in North Macedonia was reported when the breasts of a 30-year-old woman from a remote mountain village in eastern North Macedonia suddenly grew to more than 30 kilograms (66 lb) total. As the disorder becomes more widely known, media reports have increased. French Canadian Isabelle Lanthier appeared on Montel Williams' talk show where she told how her chest grew from 86 cm (34 in) to 133 cm (52 in) in five months during her pregnancy. At their largest, one breast weighed 6.8 kg (15 lb) and the other 5.4 kg (12 lb). Her husband custom-made a special bra to support her breasts. In 2007, a Chilean TV station covered the story of 32-year-old Yasna Galleguillos from Antofagasta, who experienced ongoing back pain, making everyday tasks very difficult to perform. She underwent breast reduction surgery to relieve her pain. Surgeons removed 4.25 kilograms (9.4 lb) from one breast and 3.33 kilograms (7.3 lb) from the other breast.
== Related technologies == Other devices to deliver inhaled nicotine have been developed. They aim to mimic the ritual and behavioral aspects of traditional cigarettes. British American Tobacco, through their subsidiary Nicoventures, licensed a nicotine delivery system based on existing asthma inhaler technology from UK-based healthcare company Kind Consumer. In September 2014 a product based on this named Voke obtained approval from the United Kingdom's Medicines and Healthcare Products Regulatory Agency. In 2011, Philip Morris International bought the rights to a nicotine pyruvate technology developed by Jed Rose at Duke University. The technology is based on the chemical reaction between pyruvic acid and nicotine, which produces an inhalable nicotine pyruvate vapor. Philip Morris Products S.A. created a different kind e-cigarette named P3L. The device is supplied with a cartridge that contains nicotine and lactic acid in different cavities. When turned on and heated, the nicotine salt called nicotine lactate forms an aerosol.
Sources: en.wikipedia.org
Short transit at ambient temperature is generally tolerated, but long-term storage at room temperature is not recommended. Heat, moisture, and light all accelerate degradation. Cold, dry, dark storage is the conventional choice.
Suppliers typically quote a percentage derived from reverse-phase HPLC peak area. That figure reflects the relative amount of the main peak and does not by itself confirm identity or exclude related impurities. Mass spectrometry is commonly paired with it for confirmation.
Peptides purified by reverse-phase chromatography often carry trifluoroacetate as a counter-ion, which adds mass and can affect solubility and apparent behavior in assays. Acetate and hydrochloride forms are also offered. Knowing which form is present matters when calculating how much peptide a given weight contains.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.